ArticleThe Lancet. Rheumatology2022

Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform.

Brian MacKenna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.